#1
|
|||
|
|||
Ñïëåíîìåãàëèÿ
Çäðàâñòâóéòå! Æåíùèíà, 27 ëåò, ðîñò 173, âåñ 58. Óæå ãîä èùó ïðè÷èíó óâåëè÷åííîé ñåëåçåíêè è ëåéêîïåíèè. Ñíèæåííûå ëåéêîöèòû çàìå÷åíû ñ 2017 ãîäà. È òîëüêî ãîä íàçàä òåðàïåâò ñêàçàë èñêàòü ïðè÷èíó, òîãäà è âûÿâèëè óâåëè÷åííóþ ñåëåçåíêó. Òàê æå áûëà âûÿâëåíà æä àíåìèÿ, íî ïîñëå ïðè¸ìà æåëåçà óðîâåíü ãåìîãëîáèíà è ôåððèòèíà ïðèø¸ë â íîðìó (ïðè ýòîì ðàçìåðû ñåëåçåíêè íå èçìåíèëèñü). Áûëà ó èíôåêöèîíèñòà, ãàñòðîýíòåðîëîãà, ãèíåêîëîãà- íèêòî ïðîáëåìû íå âèäèò è íàïðàâëÿþò ê ãåìàòîëîãó. Áèîõèìèÿ êðîâè â íîðìå, ñäàâàëà êàë íà ñêðûòóþ êðîâü, ÿéöà ãëèñò - âñå îòðèöàòåëüíî. Íà ôãäñ - ïîâåðõíîñòíûé ãàñòðèò. Ãèíåêîëîã êðîìå ýðîçèè íè÷åãî íå íàø¸ë. Èíôåêöèîíèñò èñêëþ÷èë ÂÈ×, ãåïàòèòû, Âèðóñ Ýïøòåéí-Áàðð. Ó ãåìàòîëîãà òîæå áûëà, îí íè÷åãî íå ñêàçàë.
Ïîäñêàæèòå, ïîæàëóéñòà, êàê èñêàòü ïðè÷èíó äàëüøå? Ãåìàòîëîãè÷åñêàÿ ëè ýòî ïðîáëåìà? Ïðèëîæèëà ðåçóëüòàòû ÎÀÊ îò 25.08.22 è 02.06.23, à òàê æå óçè îðãàíîâ áðþøíîé ïîëîñòè. |
#2
|
||||
|
||||
â ÷åì âðåìåííàÿ ðàçíèöà ìåæäó ïåðâûì è âòîðûì àíàëèçîì?
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#3
|
|||
|
|||
Âàäèì Âàëåðüåâè÷, äîáðûé âå÷åð. Èçâèíèòå, íå î÷åíü ïîíÿëà âîïðîñ. Àíàëèçû ñ ðàçíèöåé ïðèìåðíî â 9 ìåñÿöåâ. Ñòàðûé àíàëèç ïðèëîæèëà íà âñÿêèé ñëó÷àé (åãî ñäàâàëà äî ïðè¸ìà æåëåçà).
|
#4
|
||||
|
||||
ó âàñ ìîæåò áûòü êëîíàëüíàÿ ïðîëèôåðàöèÿ áîëüøèõ ãðàíóëÿðíûõ ëèìôîöèòîâ, ïðè íåé è ñïëåíîìåãàëèÿ è íåéòðîïåíèÿ
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#5
|
||||
|
||||
íå çíàþ åñòü ëè èíôà íà ðóññêîì?
Persistent Large Granular Lymphocyte Clonal Expansions [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#6
|
||||
|
||||
íà àíàëèçàõ íåò äàò, ïîåòîìó ñïðîñèë
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#7
|
|||
|
|||
Âàäèì Âàëåðüåâè÷, à äëÿ ýòîãî íóæíî åù¸ êàêèå-òî àíàëèçû ñäàòü?
|
#8
|
||||
|
||||
çäåñü ñòàòüÿ ðóññêèõ àâòîðîâ íà àíãë, ïîñìîòðèòå ïî èõ èìåíàì â ðóíåòå
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#9
|
||||
|
||||
íóæíî óçíàòü ãäå äåëàþò ìèêðîñêîïèþ áîëüøèõ êëåòîê - íå çíàþ ðîññèéñêèõ äåôèíèöèé äèàãíîçà, íî âî âñåì ìèðå ïî-ðàçíîìó - âûäåëåíî ìíîé
In the 2008 WHO Classification (3), T-LGL leukemia is defined by a persistent (>6 months) increase in the number of peripheral blood LGLs (usually 2-20×109 LGLs/L), without a clear cause. However, patients with <2×109 LGLs/L of clonally expanded LGLs are often seen, and the clinical features of these patients have been reported to be similar to those in with >2×109 LGLs/ Òanahashi et al. (33) recommended a simplified way of identifying the LGL leukemia of T- and NK-cell lineages when both of the following criteria are fulfilled: lymphocytes account for >52% of the WBC, and when >50% of the lymphocytes are LGLs. The French study group accepted, with some exceptions, the diagnostic criteria of the peripheral expansion of LGLs (>0.5×109/L) for a period of >6 months, excluding transient or reactive LGL proliferation
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#10
|
||||
|
||||
èç ðîññ. îïèñàíèÿ
All patients had marked splenomegaly without lymphadenopathy. The median white blood cell count before splenectomy was 1.2×109/L (range, 0.7-1.4×109/L). Neutropenia (<0.5×109/L) was detected in all cases; the median absolute neutrophil count was 0.136×109/L (range, 0.058-0.444×109/L). Absolute lymphocytopenia (lymphocyte count <1.0×109/L) was detected in all cases, which indicated that the number of LGLs in the peripheral blood was less than 1.0×109/L. In three cases (cases 1, 2, and 6) LGL count was less than 0.4×109/L. Monocytopenia (<0.2×109/L) was detected in six patients. The median hemoglobin level was 11 g/dL (range, 8.5-13.6 g/dL); eight patients had a hemoglobin level of <12 g/dL. The median platelet count was 116×109/L (range, 87-225×109/L); mild and moderate thrombocytopenia was detected in eight cases.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |